Serotypes and clinical manifestations of invasive group B steptococcal infections in western Sweden 1998-2001

Clinical Microbiology and Infection

Volumn 10, Issue 9, 2004, Pages 791-796

  Persson, Elisabet ^a   Berg, S ^a   Trollfors, B ^a   Larsson, P ^b   Ek, E ^b   Backhaus, E ^c   Claesson, B E B ^c   Jonsson, L ^d   Radberg G ^e   Ripa, T ^f   Johansson, S ^f  

^a QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

^d BORÅS HOSPITAL   (Sweden)

^e UDDEVALLA HOSPITAL   (Sweden)

^f HALMSTAD HOSPITAL   (Sweden)

Author keywords

Epidemiology; Group B streptococcus; Neonatal; Serotypes; Streptococcus agalactiae

Indexed keywords

POLYSACCHARIDE VACCINE; STREPTOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; ANTIGEN ANTIBODY REACTION; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEWBORN; NONHUMAN; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROTYPE; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; SWEDEN;

STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS SP. 'GROUP B';

EID: 4644360099     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00931.x     Document Type: Article

References (45)

1. Bolanos M, Canas A, Santana OE, Perez-Arellano JL, de Miguel I, Martin-Sanchez AM. Invasive group B streptococcal disease in nonpregnant adults. Eur J Clin Microbiol Infect Dis 2001; 20: 837-839.
2. Farley MM. Group B streptococcal disease in nonpregnant adults. Clin Infect Dis 2001; 33: 556-561.
3. Schwartz B, Schuchat A, Oxtoby MJ, Cochi SL, Hightower A, Broome CV. Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. JAMA 1991; 266: 1112-1114.
4. Schuchat A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 1998; 11: 497-513.
5. Blumberg HM, Stephens DS, Modansky M et al. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis 1996; 173: 365-373.
6. Davies HD, Raj S, Adair C, Robinson J, McGeer A. Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation. Pediatr Infect Dis J 2000; 20: 879-884.
7. Tyrrell GJ, Senzilet LD, Spika JS et al. Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study - 1996. Sentinel Health Unit Surveillance System Site Coordinators. J Infect Dis 2000; 182: 168-173.
8. Moyo SR, Maeland JA, Bergh K. Typing of human isolates of Streptococcus agalactiae (group B streptococcus, GBS) strains from Zimbabwe. J Med Microbiol 2002; 5: 595-600.
9. Farley MM, Harvey RC, Stull T et al. A population-based assessment of invasive disease due to group B streptococcus in nonpregnant adults. N Engl J Med 1993; 328: 1807-1811.
10. Harrison LH, Elliott J, Dwyer DM et al. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. J Infect Dis 1998; 177: 998-1002.
11. Lachenauer CS, Kasper DL, Shimada J et al. Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis 1999; 179: 1030-1033.
12. Berg S, Trollfors B, Lagergard T, Zackrisson G, Claesson BA. Serotypes and clinical manifestations of group B streptococcal infections in western Sweden. Clin Microbiol Infect 2000; 6: 9-13.
13. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294: 753-756.
14. Klegerman ME, Boyer KM, Papierniak CK, Levine L, Gotoff SP. Type-specific capsular antigen is associated with virulence in late-onset group B streptococcal type III disease. Infect Immun 1984; 44: 124-129.
15. Lin FY, Philips JB, Azimi PH et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis 2001; 184: 1022-1028.
16. Baker CJ, Kasper DL, Tager IRAB et al. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B streptococcus. J Clin Invest 1977; 59: 810-818.
17. Kasper DL, Paoletti LC, Wessels MR et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996; 98: 2308-2314.
18. Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med 1988; 319: 1180-1185.
19. Baker CJ, Paoletti LC, Wessels MR et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999; 179: 142-150.
20. Paoletti LC, Kasper DL. Conjugate vaccines against group B streptococcus types IV and VII. J Infect Dis 2002; 186: 123-126.
21. Paoletti LC, Peterson DL, Legmann R, Collier RJ. Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. Vaccine 2001; 20: 370-376.
22. Kotloff KL, Fattom A, Basham L, Hawwari A, Harkonen S, Edelman R. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults. Vaccine 1996; 14: 446-450.
23. Paoletti LC. Potency of clinical group B streptococcal conjugate vaccines. Vaccine 2001; 19: 2118-2126.
24. American College of Obstetricians and Gynecologists. ACOG Committee Options 279. Prevention of early-onset Group B streptococcal disease in newborns. Obstet Gynecol 2002; 100: 1405-1412.
25. Håkansson S, Burman LG, Henrichsen J, Holm SE. Novel coagglutination method for serotyping group B streptococci. J Clin Microbiol 1992; 30: 3268-3269.
26. Williams R. Laboratory diagnosis of streptococcal infections. Bull WHO 1958; 19: 153-176.
27. Rotta J, Krause RM, Lancefield RC, Everly W, Lackland H. New approaches for the laboratory recognition of M types of group A streptococci. J Exp Med 1971; 134: 1298-1315.
28. Dahl M, Tessin I, Trollfors B. Invasive group B streptococcal infections in Sweden: incidence, predisposing factors and prognosis. Int J Infect Dis 2003; 7: 113-119.
29. Tessin I, Trollfors B, Thiringer K. Incidence and etiology of neonatal septicaemia and meningitis in Western Sweden 1975-86. Acta Paediatr Scand 1990; 79: 1023-1030.
30. Persson E, Trollfors B, Lind Brandberg L, Tessin I. Septicaemia and meningitis in neonates and during early infancy in the Göteborg area of Sweden. Acta Paediatr 2002; 91: 1087-1092.
31. Kalliola S, Vuopio-Varkila J, Takala A, Eskola J. Neonatal group B streptococcal disease in Finland: a ten-year nationwide study. Pediatr Infect Dis J 1999; 18: 806-810.
32. Schrag S, Zywicki S, Farley M et al. Streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342: 15-20.
33. Hervás J, Gonzáles L, Gil J, Paoletti L, Madoff C, Benedí V. Neonatal group B streptococcal infection in Mallorca, Spain. Clin Infect Dis 1993; 16: 714-718.
34. Jelinkova J, Motlova J. Worldwide distribution of two new serotypes of group B streptococci: type IV and provisional type V. J Clin Microbiol 1985; 21: 361-362.
35. Ko WC, Lee HC, Wang LR, Lee CT, Liu AJ, Wu JJ. Sero-typing and antimicrobial susceptibility of group B streptococcus over an eight-year period in southern Taiwan. Eur J Clin Microbiol Infect Dis 2001; 20: 334-339.
36. Davies D, Adair C, McGeer D et al. Antibodies to capsular polysaccharides of group B streptococcus in pregnant Canadian women: relationship to colonization status and infection in the neonate. J Infect Dis 2001; 184: 285-291.
37. Lin FY, Clemens JD, Azimi PH et al. Capsular polysaccharide types of group B streptococcal isolates from neonates with early onset systemic infection. J Infect Dis 1998; 177: 790-792.
38. Campell J, Hillier S, Krohn M, Ferrieri P, Zaleznik D, Baker CJ. Group B streptococcal colonization and serotype-specific immunity in pregnant women at delivery. Obstet Gynecol 2000; 96: 498-503.
39. Bevanger L, Iversen O-J, Naess AI. Characterization of the α-antigen of the c proteins of group B streptococci (GBS) using a murine monoclonal antibody. APMIS 1995; 103: 731-736.
40. Bevanger L. The Ibc proteins of group B streptococci: isolation of the α and β antigens by immunosorbent chromatography and test for human serum antibodies against the two antigens. Acta Pathol Microbiol Immunol Scand B 1985; 93: 113-119.
41. Lancefield RC, Perlmann GE. Preparation and properties of a protein (R antigen) occurring in streptococci of group A type 28 and in certain streptococci of other serological groups. J Exp Med 1952; 96: 83-97.
42. Bevanger L, Kvam AI, Maeland JA. A Streptococcus agalactiae R protein analyzed by polyclonal and monoclonal antibodies. APMIS 1995; 103: 731-736.
43. Stålhammar-Carlemalm M, Stenberg L, Lindahl G. Protein Rib: a novel group B streptoccocal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infection. J Exp Med 1993; 177: 1593-1603.
44. Brodeur B, Boyer M, Charlebois I et al. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect Immun 2000; 68: 5610-5618.
45. Martin D, Rioux S, Gagnon E et al. Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein. Infect Immun 2002; 70: 4897-4901.